YKL-5-124

• CAT Number: I014834
• CAS Number: 1957203-01-8
• Molecular Formula: C₂₈H₃₃N₇O₃
• Molecular Weight: 515.61
• Purity: ≥95%
• Storage: Store at -20°C
• IUPAC Name: N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[[4-(prop-2-enoylamino)benzoyl]amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide
• InChI: InChI=1S/C28H33N7O3/c1-6-23(36)29-20-14-12-19(13-15-20)26(37)31-25-21-16-35(28(2,3)24(21)32-33-25)27(38)30-22(17-34(4)5)18-10-8-7-9-11-18/h6-15,22H,1,16-17H2,2-5H3,(H,29,36)(H,30,38)(H2,31,32,33,37)/t22-/m1/s1
• InChIKey: KPABJHHKKJIDGX-JOCHJYFZSA-N
• SMILES: CC1(C2=C(CN1C(=O)NC(CN(C)C)C3=CC=CC=C3)C(=NN2)NC(=O)C4=CC=C(C=C4)NC(=O)C=C)C

YKL-5-124（Cat No.:I014834）is a highly selective, potent inhibitor of CDK7 (cyclin-dependent kinase 7), an enzyme crucial for regulating transcription and the cell cycle. By inhibiting CDK7, YKL-5-124 disrupts transcriptional initiation and elongation, particularly affecting the expression of oncogenes and genes involved in cancer cell proliferation. This compound induces cell cycle arrest and apoptosis in rapidly dividing cancer cells, making it a valuable tool for cancer research. YKL-5-124 is being explored as a potential therapeutic agent for targeting transcriptionally addicted cancers, where abnormal transcription is a key driver of tumor growth.

Reference

[1]. Olson CM, et al. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chem Biol. 2019 Jun 20;26(6):792-803.e10.